Therapeutic effect of the co-administrated metformin and rosiglitazone in treatment of type 2 diabetes mellitus
- VernacularTitle:二甲双胍联用罗格列酮治疗2型糖尿病疗效观察
- Author:
Hong FAN
;
Huwei SHEN
;
Jin LI
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Insulin resistance;
Rosiglitazone;
Metformin;
Glipizide
- From:
Chinese Journal of Diabetes
2008;16(5):278-279
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the therapeutic effect of co-administrated metformin and rosiglitazone in the treatment of type 2 diabetes mellitus(T2DM).Methods 53 patients with T2DM were divided into 2 groups in random:co-administrated glipizide and metformin(group A)and co-administrated metformin and rosiglitazone(group B).All cases were treated for 6 months.Blood pressure(BP),blood glucose(BG),body mass index(BMI),hemoglobin A1c(HbA1c),insulin,and blood lipid were determined and the HOMA-insulin resistance index(HOMA-IR)was calculated.Results Both treatments were effective on hyperglucose,hypertension,hyperlipidemia and high BMI(P<0.05-0.01),while group B could lower the level of insulin(P<0.05)and HOMA-IR(P<0.01).Conclusions Treatment of co-administrated metformin and rosiglitazone can improve the abnormal carbohydrate and lipid metabolism,higher levels of BP and BMI,and ameliorate insulin resistance.
